Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells. by Zeng, Yang et al.
UC Merced
UC Merced Previously Published Works
Title
Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional 
validation of human immunity after transfer of HLA-matched human cells.
Permalink
https://escholarship.org/uc/item/5ff0c08q
Journal
PloS one, 12(4)
ISSN
1932-6203
Authors
Zeng, Yang
Liu, Bingrun
Rubio, Marie-Thérèse
et al.
Publication Date
2017
DOI
10.1371/journal.pone.0173754
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Creation of an immunodeficient HLA-
transgenic mouse (HUMAMICE) and
functional validation of human immunity after
transfer of HLA-matched human cells
Yang Zeng1,2, Bingrun Liu2, Marie-The´rèse Rubio3, Xinyue Wang2, David M. Ojcius4,
Ruoping Tang5, Antoine Durrbach2,6, Zhitao Ru1,2, Yusen Zhou1, Yu-Chun Lone2*
1 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology,
Beijing, China, 2 INSERM U1197 (ex U1014), Hospital Paul Brousse, University of Paris-Sud, Universite´
Paris-Saclay, Villejuif, France, 3 Service d’He´matologie de me´decine interne, Hoˆpital Brabois, CHRU Nancy,
Vandoeuvre les Nancy, France. And CNRS UMR 7365, IMoPa, Biopole de l’Universite´ de Lorraine,
Vandoeuvre les Nancy, France, 4 Department of Biomedical Sciences, University of the Pacific, Arthur
Dugoni School of Dentistry, San Francisco, CA, United States of America, 5 Tumorothèque du service
d’He´matologie de l’Hoˆpital Saint-Antoine. Assistance Publique-Hoˆpitaux de Paris (AP-HP), Paris, France,
6 IFRNT, Nephrology department, Le Kremlin Bicetre, Universite Paris-Sud, France
* yu-chun.lone@inserm.fr
Abstract
Research on human immunology has been hindered by the lack of optimal small animal
models, given that the protective immune responses of human and non-human species
show significant differences. However, due to ethical constraints[1] and the high cost of clini-
cal trials, it is urgent to improve the current animal models that can mimic faithfully human
physiology, particularly the human immune system (HIS). HIS mice had been generated
recently by engrafting human hematopoietic stem cells (hHSCs) or human peripheral mono-
nuclear cells (hPBMCs) into highly immuno-deficient mice such as NSG, NOG or NRG
mice. However, a major experimental drawback for studies using these models is the rapid
onset of Graft-versus-Host Disease (GvHD). In the present study, we overcome this limita-
tion by generating new immuno-deficient mice named "HUMAMICE" (HLA-A2+/+/DR1+/+/H-
2-β2m-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/- mice), which expressed human HLA molecules instead
of mouse MHC molecules (H-2), and whose immuno-deficient status was reversed by trans-
ferring functional HLA-matched PBMCs thus producing mice with an immuno-competent
status with a functional human immune system. We showed that in this HLA-matched con-
text, the hPBMC-transfer led to high lymphocytes engraftment rates without GvHD over
three months in this novel mouse model. Furthermore, to evaluate the utility of the hPBMC-
HUMAMICE, we immunized them with commercial vaccine of Hepatitis B virus (HBsAg,
Hepvac@) which resulted in robust and reproducible production of high levels of HBsAg-
specific antibodies, implying that both transferred T and B lymphocytes were functional
in HUMAMICE. These responses are comparable to those observed in human clinical
trials with this identical vaccine. In conclusion, these findings indicated that the HLA-
matched-hPBMC-HUMAMICE represents a promising model for dissecting human immune
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responses in various human diseases, including infectious diseases, cancers and tumors,
and to facilitate the development of novel vaccines and cellular therapies.
Introduction
Mice functionally engrafted with human hematopoietic cells (hHSCs) may represent a valuable
preclinical tool for basic and applied investigations of the human immune system[2]. The cur-
rent reference models for such humanized mice involved grafting a functional human immune
system into the immuno-deficient mice, for example, NSG [3], NOG, NRG, Rag2-/- [4] and
IL2rγ-/- mice [5–7] (these highly immuno-deficient mice lack almost the entire mouse-derived
immune system, including murine B cells, T cells, and natural killer cells). These models have
certain advantages for fostering the survival and expansion of human donor cells, but also
have several limitations and drawbacks[8,9]. However, the maintenance of HLA compatibility
is necessary for ensuring the proper function of a normal human immune system in a murine
genetic background. Indeed, after hPBMC transferred, a constant and rapid onset of xenogenic
Graft-versus-Host Disease (xeno-GvHD[10]) was observed in all hPBMC-humanized mice.
This complication caused researchers to avoid these models for studies of the human immune
system [11], in particular, to explore responses against infections such as human-tropic infec-
tious diseases (caused by Epstein–Barr virus and HIV[12]). Consequently, the models are not
used in the development of vaccines and cell or gene therapies[13].
Nonetheless, these PBMC-humanized mice are still an excellent xeno-GvHD model for
evaluating therapeutic strategies that could interfere with xeno-GvHD development. Unfortu-
nately, while the transfer of hPBMC leads to high lymphocytes engraftment rates, the time-
frame for experimental intervention and analysis is somewhat limited, because of the rapid
development of xenogenic GvHD.
The principal host components responsible for triggering GvHD are the xenogenic
mouse MHC (H-2) class I and class II molecules. Studies with NSG mice lacking H-2 class I
(β2m
null) or H-2 class II (IAβnull) showed that the deletion of H-2 class I and II molecules
could delay the occurrence of the diseases significantly compared with WT NSG mice, but
could not abrogate it completely[14,15]. By contrast, H-2 class I-deficient NSG mice were
relatively resistant to the development of xeno-GvHD. These data indicated that both
donors’ CD8+ and CD4+ T cells contribute significantly to development of xenogeneic
GvHD and revealed the critical role of H-2 class I and class II molecules in the development
of xeno-GvHD in mice. Furthermore, in contrast to the repopulation of NRG mice with
xenogeneic human DQ8-PBMCs which resulted in rapid induction of xeno-GvHD and
poor survival rate of the animals, the transfer of HLA-class II-matched human DQ8-PBMCs
into NRG IAβ–/–DQ8 transgenic recipients (lacking the expression of murine H-2 class II
molecules, and expressing a transgenic HLA-DQ8 molecule) resulted in a milder form of
xeno-GvHD, such that the mice survived significantly longer than other previous mouse
models. These data showed that HLA compatibility between donors and recipients is a
requirement for ensuring a proper function of human immune systems in mice without the
emergence of graft rejection.
Previously, we have developed an HLA class I and class II transgenic mouse (Sure-L1 mice)
(HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-) which lacked both murine H-2 class I and II mole-
cules, and instead expressed HLA-A2 and HLA-DR1 molecules[16]. In this humanized mouse
model, murine T cells could only mount HLA-restricted responses without H-2-restricted
Mouse model for studying human immunity
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responses, demonstrating that the expression of both transgenic HLA class I and II molecules
could result in proper thymic education and differentiation of developing T lymphocytes.
In this study, we describe a novel mouse strain derived from the Sure-L1 mouse (HLA-
A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-), in which we additionally depleted the murine Rag 2 allele,
the interleukin 2 receptor gamma chain allele (IL2rγ) and the perforin allele (Perf), leading to
the generation of immuno-deficient mice (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-/Rag2-/-/
IL2rγ-/-/Perf-/- mice) which named HUMAMICE.
Furthermore, we confirmed that the transfer of HLA-matched hPBMCs into this HUMA-
MICE can generate a functional human immune system without signs compatible with onset
of Graft-versus-Host Disease (GvHD) including the pathological symptoms like weight loss,
diarrhea, alopecia or the immunological signs like infiltration of activated human lymphocytes
in liver, skin, or intestine.
Therefore, the HLA-matched-hPBMC-HUMAMICE model opens the possibility of study-
ing not only normal human immune-hematopoietic development but also human disease
pathogenesis for a broad range of biomedical applications.
Methods
Ethics statement
Experimental procedures were approved by the Animal Care Committee of the University
Paris-Sud Network, and carried out in accordance with Animal Care Guidelines. Human
PBMCs were collected from healthy volunteers (with written informed consent, that these doc-
uments are recorded in tumorotheque of hopital saint Antoine) in Hospital Saint Antoine and
in compliance with French and European regulations. Tumorotheque of hopital saint Antoine
’s review board specifically approved the study regarding the collection of Human PBMCs
valid until June 30th, 2016
Mice
HUMAMICE (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/- mice) were
generated on the background of Sure-L1 mice (HLA-A2+/+/DR1+/+/β2m
-/-/IAβ-/-) to homozy-
gosity. The construction of SURE-L1 mice was fully described previously16. In brief, we estab-
lished the homozygous SURE-L1 mice by intercrossing the HLA-A2.1 (HHD)-transgenic H-2
class I-KO (β2m
-/-) mice (genetic background of C57BL/6 backcrossed 9 generation) with
HLA-DR1-transgenic H-2 class II-KO (IAβ-/-) mice (genetic background of C57BL/6 back-
crossed for 7 generation). HUMAMICE was produced by several intercrossings between Sure-
L1 mice with Rag2
null
mice, IL2rγ
null
mice and Perf
null
mice. The obtained final homozygote
HUMAMICE (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/-) were checked by
both specific PCR molecular genotyping and FACS analysis after specific immune-labelling
(data not shown).
HUMAMICE were bred and housed under specific pathogen-free (SPF) conditions in iso-
lators in the animal facility at the TAAM Orle´ans center, and using sterile techniques and
micro-isolator caging. Experimental procedures were approved by the Animal Care Commit-
tee of the University Paris-Sud Network, and carried out in accordance with Animal Care
Guidelines. Six to eight week-old female mice were used as transplantation recipients. The
endpoint for the survival study was set when recipient mice looked clinically ill or lost more
than 15% of body weight, and mice were humanely sacrificed by cervical dislocation under
general anesthetic or CO2.
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PLOS ONE | https://doi.org/10.1371/journal.pone.0173754 April 11, 2017 3 / 17
Genotype identification of HUMAMICE
The transgenic of HLA-A2 and HLA-DR1, as well as the knockout of H-2-β2m, H-2-IAβ,
Rag2, IL2rγ and Perf were identified by specific PCR test. Murine genomic DNA was extracted
as described previously[17]. The immuno-deficiency characteristic of HUMAMICE was
checked by flow cytometry, while the immuno-competent C57BL/6 mice were chosen as the
controls. Splenocytes were labelled with mCD3-PE and mCD19-FITC, mCD4-APC and
mCD8-PE-Cy5.
The identification of the immuno-deficiency of HUMAMICE
To confirm the immuno-deficiency status of HUMAMICE, we engrafted the subcutaneously
the human RAMOS tumor cells (107 cells) into HUMAMICE and immuno-competent paren-
tal Sure-L1 mice. Furthermore, to verify that the inability of HUMAMICE to reject RAMOS
cells is due to lack of the mouse-derived immune system, 30 days after the injection of
RAMOS cells, we transferred total splenocytes, purified CD8+ T lymphocytes or other lympho-
cytes derived from immuno-competent HLA-A2/DR1 mice which had rejected RAMOS cells
into HUMAMICE carrying a solid tumor. Moreover, we surveyed and measured the volume
of tumors constantly.
Collection and purification of human PBMC
Human PBMCs were collected from healthy volunteers in Hospital Saint Antoine and compli-
ance with French and European regulations. PBMCs were purified by Ficoll-Hypaquedensity
centrifugation and suspended in PBS.
HLA genotyping
The HLA-A0201 (HLA-A2) positive individuals were identified by flow cytometry. And the
DNA was extracted from 1×106donor hPBMCs using the DNeasy Blood & Tissue Kit (Qia-
gen). The HLA-DRB1-01 (HLA-DR1) positive individuals were identified by specific polymer-
ase chain reaction (PCR) using Olerup SSP DR low resolution and high solution SSP DRB1:01
kit following the instructions.
Xenogenic hPBMC transplantation
Female 6- to 8-week-old HUMAMICE were irradiated with 3 Gy using a cobalt radiation
source shortly the day before cell transfer (Precision X-RAD 320 Biological Irradiator) and
were followed given by intravenous injection of 107 hPBMC cells with a total volume of 100 μL
per recipient mouse. After transplantation, mice were given sterile water containing prophy-
lactic neomycin sulfate. And mice were monitored for weight and clinical symptoms twice per
week. Weight loss of> 15% of original starting weight is a sign of GvHD development and
necessitates euthanasia of the PBMC-engrafted mice.
Two independent experiments with two different donors were performed using a group of
5 or 4 mice. For HLA-A2+/DR1+ donor A, we transferred with 5 mice. Three HUMAMICE
were analyzed at five weeks post hPBMC transfer, and two were sacrificed at 8 weeks post
hPBMC transfer for FACS analysis. For HLA-A2+/DR1+ donor B, we transferred with 4 mice.
HUMAMICE (2 at 5 weeks post hPBMC transfer, 1 mouse at 8 weeks and 1 mouse at 12 weeks
post hPBMC transfer) were sacrificed for FACS analysis.
Mouse model for studying human immunity
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Immunization of HUMAMICE
Fourteen days after the transplantation of hPBMCs, HUMAMICE received three intramuscu-
lar (i.m.) injections of recombinant HBV vaccine (10 μg) (Pasteur Institute) in a total injected
volume of 100 μL. Each immunization was separated by an interval of 14 days. Sera were col-
lected both before and after each immunization boost for serological analysis. Mice were sacri-
ficed 10 days after the final boost.
Flow cytometry
To detect human cells engrafted in HUMAMICE, multi-colors cytometric analysis was per-
formed using BD LSR Fortessa, according to the manufacturer’s protocol but with a minor
modification. HUMAMICE were sacrificed and the spleens were removed at three different
times after hPBMCs were transplanted. Splenocytes were collected and lysed by ACK lysis
buffer, counted and incubated with an appropriate volume of antibodies for 1 hour at 4˚C and
then subjected to flow cytometry analysis.
Commonly used antibodies included: Anti-Human CD45 FITC, Clone: 2D1, (ebio-
science9011-9459); isotype control, Mouse IgG1 K Isotype Control (ebioscience, FITC 11–
4714) ; Anti-Mouse CD45 eFluor1 450 (ebioscience, 48-0451-82) ; isotype control, Mouse
IgG2b K Isotype Control eFluor1 450 (ebioscience, 48-4732-82) ; Anti-Human CD3 APC-
eFluor1 780, Clone: UCHT1, (ebioscience, 47–0038) ; Mouse IgG1 K Isotype Control APC-
eFluor1 780 (ebioscience, 47–4714) ; Anti-Human CD4 PerCP-Cyanine5.5, Clone: OKT4
(OKT-4), (ebioscience, 45–0048); isotype control, Mouse IgG2b K Isotype Control PerCP-Cya-
nine5.5 (cat. 45–4732) ; Anti-Human CD8a PE-Cyanine7, Clone: SK1, (ebioscience, 25–0087);
isotype control, Mouse IgG1 K Isotype Control PE-Cyanine7 (ebioscience, 25–4714) ; Anti-
Human CD19 APC, Clone: 2H7, (ebioscience, 17–0209); isotype control, Mouse IgG1 K Isotype
Control APC (ebioscience, 17–4714).
Measurement of serum antibodies by ELISA
The serum levels of antibodies specific for the commercial HBsAg vaccine in immunized
HUMAMICE were measured by ELISA test. The plates coated with the HBsAg vaccine were
blocked with PBS supplemented with 0.1% Tween20 and 10% FCS and then washed three
times. After the addition of mouse serum for 1 h, the plates were washed again, and bound
antibodies were detected with Anti-Human IgG (whole molecule)-Peroxidase antibody pro-
duced in rabbit (SIGMA-ALDRICH, A8792) and Anti-Human IgM (μ-chain specific)-Peroxi-
dase antibody produced in goat-affinity isolated antibody (SIGMA-ALDRICH, A6907).
Absorbance was then measured at 450nm in a plate reader. The antibody titers (the mean of at
least three determinations) were calculated using the serial end-point dilution method.
Statistical analysis
Each experiment was repeated at least three times, and data were expressed as the
mean ± SEM. The means or geometric means of multiple groups were compared using Stu-
dent’s t-test. All statistical analysis was performed using GraphPad Prism version 5.0. A P
value<0.05 was considered statistically significant.
Results
Generation and characterization of HUMAMICE
Based on the background of Sure-L1 mice (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/- mice), we
generated the humanized mice “HUMAMICE”. This was achieved by several rounds of
Mouse model for studying human immunity
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intercrossing between Sure-L1 mice with Rag2-/- mice, IL2rγ-/- mice and Perf-/- mice. The
resulting homozygote HUMAMICE (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/
Perf-/-) were determined by both specific PCR molecular genotyping and FACS analysis after
specific immune-labelling (data not shown).
We confirmed the immuno-deficiency characteristics of HUMAMICE by flow cytometry.
Highly immuno-deficient mice such as NOG/NSGmice are characterized by the lack of almost
the entire mouse-derived immune system, including murine B cells, T cells, and NK cells.
Comparative cell analysis by flow cytometry between splenocytes from immuno-deficient
HUMAMICE and immuno-competent C57BL/6 mice were shown in Fig 1. Representative
immuno-competent C57BL/6 mice expressed 24.9% mCD3+ T cells and 52.3% mCD19+ B
cells; while only a residual population (<0.5%) for both mCD3+ T cells and mCD19+ B cells
was found in immuno-deficient HUMAMICE (Fig 1A). The ratio of mCD4+/mCD8+ T cells
in C57BL/6 mice was 1.85 (54.1%/29.2%) (Fig 1B, right) and there were neither CD4+ nor
CD8+ T cells in HUMAMICE (Fig 1B left). The absence of murine T cells (CD3+CD4+ T cells
and CD3+CD8+ T cells) and B cells (CD19+CD20+) is an important requirement for the
immuno-deficient status of these mice. Table 1 summarizes the results for other cell popula-
tions after the hPBMC engraftment. We noted, in particular, the absence of NK cells in
HUMAMICE (0%) compared with immuno-competent C57BL/6 mice (1.9% and 2.4%). The
consequence of this lack of almost the entire mouse-derived immune system is the sign of
severe immune-deficiency characterized by the inability to reject foreign cells.
Confirmation of the immuno-deficiency of HUMAMICE
To confirm the immuno-deficiency status of HUMAMICE, we engrafted subcutaneously
human RAMOS tumor cells (107cells/mouse) into HUMAMICE and immuno-competent
parental Sure-L1 mice. Fig 2A (left) shows the kinetics of RAMOS tumor growth in six
HUMAMICE (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/-) (mouse No.912;
926; 953; 952; 948; 950), whereas Fig 2A (right) shows the tumor size in five immuno-compe-
tent Sure-L1 mice (HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-). In addition, Fig 2B shows the
RAMOS cells tumor subcutaneous development in six HUMAMICE and five Sure-L1 mice
during 25 days post the injection. Overall, tumors were not able to grow in immuno-compe-
tent mice whereas they induced tumors in HUMAMICE. Furthermore, to verify that the
inability of HUMAMICE to reject RAMOS cells is due to lack of the mouse-derived immune
system, we transferred total splenocytes, purified CD8+ T lymphocytes or purified CD8- T
lymphocytes derived from the immuno-competent Sure-L1 mice which had rejected the
RAMOS cells into HUMAMICE that developed a solid tumor. Results of the kinetics of tumor
growth after the transfer of total splenocytes, purified CD8+ T lymphocytes or purified CD8-
T lymphocytes from immuno-competent tumor-primed Sure-L1 mice are shown in Fig 3A,
3B and 3C, respectively. In Fig 3A, three immuno-deficient HUMAMICE bearing a solid
RAMOS tumor (mouse No.926; 948; 952) rejected completely their tumors 15 days after cell-
transfer of total splenocytes from immuno-competent tumor-primed Sure-L1 mice, while the
volume of the tumor continued to grow in mouse (No.953) which did not receive cell transfer.
Fig 3B shows the example of HUMAMICE (No.208 and No.326) which bore solid RAMOS
tumors. After the transfer of CD8+ purified T lymphocytes from immuno-competent tumor-
primed Sure-L1 mice, only mouse No.326 could reject completely the tumors in 12 days,
whereas mouse No.208 could only stop the tumor growth at 6 days and stabilized the tumor
size without total rejection, compared with control mouse No.323 which did not receive cell
transfer and in which the tumor continued to grow. As shown in Fi 3C, after receiving purified
CD8- T lymphocytes, from immuno-competent tumor-primed Sure-L1 mice, HUMAMICE
Mouse model for studying human immunity
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(No.139, 212 and 337) bearing a solid RAMOS tumor started to reject their tumors by reduc-
ing progressively their size from 6 days post-transfer, while the tumors continued to grow in
Fig 1. Flow cytometry analysis of immuno-deficient HUMAMICE. Comparative cell analysis by flow cytometry between immuno-deficient
HUMAMICE (HLA-A2+/+/DR1+/+/H-2-β2m-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/-) and immuno-competent C57BL/6 mice. The left panel shows the
analysis of immuno-deficient HUMAMICE and the right panel was the immuno-competent C57BL/6 mice. (A) Samples in Fig 1A were double-
labelled with mCD3-PE and mCD19-FITC. (B) Samples in Fig 1B were labelled with mCD4-APC and mCD8-PE-Cy5.
https://doi.org/10.1371/journal.pone.0173754.g001
Mouse model for studying human immunity
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control mouse No.323 that did not receive cell transfer. Altogether, these results confirm that
HUMAMICE are severely immuno-deficient.
hPBMC engraftment in HUMAMICE
In order to evaluate the engraftment of HLA-matching hPBMCs in this new immuno-deficient
HLA-humanized mouse model, we transferred 107 HLA-matched (HLA-A2+DR1+) hPBMCs
intravenously into HUMAMICE after a total body irradiation and monitored the weight of
Table 1. Summary of comparative cell analysis was implemented by flow cytometry between immuno-deficient HUMAMICE and immuno-compe-
tent C57BL/6 mice.
Cellular type HUMAMICE-1 HUMAMICE-2 C57BL/6 mice-1 C57BL/6 mice-2
mCD45+ 44.9% 32.1% 88.8% 95%
mCD3+mCD4+ 0.4% 0.2% 13.5% 27.5%
mCD3+mCD8+ 0.4% 0.5% 7.3% 17.1%
mCD19+mCD20+ 0.1% 0% 52.3% 32%
mCD19-mCD20+ 0.1% 0.7% 2.4% 2.5%
NKp46+NK1.1+ 0% 0% 1.9% 2.4%
Ter119+ 18.2% 30.8% 5% 5.7%
CD11b+ 9.4% 8.5% 6.4% 8.5%
The populations mCD45+; mCD3+mCD4+; mCD3+mCD8+; mCD19+mCD20+; mCD19-mCD20+; NKp46+NK1.1+; Ter119+; are CD11b+are presented.
https://doi.org/10.1371/journal.pone.0173754.t001
Fig 2. The tumor growth kinetics in immuno-deficient HUMAMICE and immuno-competent Sure-L1 mice after subcutaneous injection of
RAMOS tumor cells. (A) Comparative tumor growth in six immuno-deficient HUMAMICE (HLA-A2+/+/DR1+/+/H-2-β2m-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/-) and
five immuno-competent Sure-L1 mice (HLA-A2+/+/DR1+/+/H-2-β2m-/-/IAβ-/-) 25 days after the subcutaneous injection of RAMOS cells. Fig 2A (left) and B
(left) show HUMAMICE; while Fig 2A (right) and B (right) show Sure-L1 mice.
https://doi.org/10.1371/journal.pone.0173754.g002
Mouse model for studying human immunity
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mice and clinical GvHD signs once a week as described previously[18]. The experimental pro-
tocol is summarized in Fig 4.
Flow cytometry analysis was done at five, eight weeks and three months after the hPBMC
were transferred (Shown in Table 2). Results of two representative mice (from nine analyzed
mice) which were analyzed at five and eight weeks after transplantation are shown in Fig 5.
For the mouse that was analyzed at 5 weeks after transplantation (Fig 5A), 11.6% of splenocytes
were composed by human CD45+ cells, with 45.2% of this population being hCD19+, and
17.1% of this population being hCD45+hCD3+ T lymphocytes: 29.0% of them were hCD8+ T
lymphocytes (hCD45+hCD3+hCD8+) and approximately 60.9% were hCD4+ T lymphocytes
(hCD45+hCD3+hCD4+). For the mouse which was analyzed at 8 weeks after transplantation
(Fig 5B), 9.7% of splenocytes were composed by hCD45+ cells, with 49.4% of this population
being hCD19+ B cells, and 16.1% of this population being hCD45+hCD3+ T lymphocytes:
30.0% of them were hCD8+ T lymphocytes (hCD45+hCD3+hCD8+) and approximately 59.0%
were hCD4+ T lymphocytes (hCD45+hCD3+hCD4+). The constitutions of splenocytes of
hPBMC-transplanted HUMAMICE were shown in Table 2. Moreover, none of the HUMA-
MICE developed GvHD signs or weight loss (shown in Fig 6).
The humoral immune response of HUMAMICE to a specific HBsAg
vaccine
We next evaluated the functional ability of these adoptively transferred HLA-matched-
hPBMCs in HUMAMICE to respond to a specific antigenic stimulus, namely HBsAg vaccine.
The schedule of immunization with the HBsAg vaccine is shown in Fig 4 and included a pri-
mary immunization two weeks after hPBMC transfer, followed by two immunization boosts
every two weeks after primary immunization. The collected sera were analyzed with an HBsAg
specific ELISA test according to the protocol described in Material and Methods. The back-
ground noise was represented by the mean of two HUMAMICE controls without transfer
of hPBMCs. Fig 7A and 7B showed the HBsAg-specific-hIgG and HBsAg-specific-hIgM
responses of immunized hPBMC-HUMAMICE before (0 w) and every two weeks after immu-
nization (before each immunization boost). We observed a significant HBsAg-specific hIgG
response which was amplified after recall immunization boots. And HBsAg-specific-IgM
Fig 3. The tumor growth kinetics in HUMAMICE after transfer of RAMOS specific splenocytes from parental Sure-L1 mice. (A) Tumor growth
kinetics following transfer of tumor specific splenocytes from Sure-L1 mice in three immuno-deficient HUMAMICE bearing a solid RAMOS tumor (mouse
No.926; 948; 952) and the control mouse No.953 without the transfer of tumor-bearing cells. (B) Tumor growth kinetics following transfer of purified tumor
specific CD8+ T lymphocytes from Sure-L1 mice in two immuno-deficient HUMAMICE bearing a solid RAMOS tumor (mouse No.208 ; 326) and the control
mouse No.323 without transfer of tumor-bearing cells. (C) Tumor growth kinetics following transfer of tumor specific splenocytes depleted of CD8+ T cells
(purified CD8- T lymphocytes) from Sure-L1 mice in three immuno-deficient HUMAMICE bearing a solid RAMOS tumor (mouse No.139; 212; 337) and the
control mouse No.323 without transfer of tumor-bearing cells.
https://doi.org/10.1371/journal.pone.0173754.g003
Mouse model for studying human immunity
PLOS ONE | https://doi.org/10.1371/journal.pone.0173754 April 11, 2017 9 / 17
responses were detected after the primary-immunization, while no more responses were
observed after recall immunization.
Discussion
The development of small animal models that could mimic human immune responses is
important to evaluate novel human useful clinical drugs or test new therapeutic treatments or
Fig 4. The experimental procedure of hPBMC transplantation and immunization with HBsAg vaccine in HUMAMICE.
https://doi.org/10.1371/journal.pone.0173754.g004
Table 2. Summary of all the HUMAMICE transplanted with HLA-A2+/DR1+ hPBMCs.
Donor A/mouse mCD45-hCD45+ hCD45+hCD19+ hCD45+hCD3+ hCD3+hCD4+ hCD3+hCD8+
Mouse 1 (5 weeks) 11.6% 45.2% 17.1% 60.9% 29.0%
Mouse 2 (5 weeks) 13.4% 51.9% 15.4% 68.3% 24.6%
Mouse 3 (5 weeks) 15.2% 56.7% 18.9% 52.4% 22.8%
Mouse 4 (8 weeks) 9.7% 49.4% 16.1% 59.0% 30.0%
Mouse 5 (8 weeks) 7.1% 60.8% 13.2% 40.9% 15.8%
Donor B/Mouse
Mouse 6 (5 weeks) 19.2% 69.2% 14.7% 63.1% 20.9%
Mouse 7 (5 weeks) 15.8% 54.2% 15.1% 60.7% 19.2%
Mouse 8 (8 months) 8.9% 51.2% 20.7% 40.9% 12.1%
Mouse 9 (12 weeks) 5.4% 42.1% 12.2% 19.5% 4.5%
https://doi.org/10.1371/journal.pone.0173754.t002
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new vaccines. In this paper, we show that HUMAMICE developed by backcrossing derived
Sure-L1 mice with Rag2-/- mice, IL2rγ-/- mice and Perf-/- mice can be efficiently reconstitute
with HLA-matched PBMCs without developing GvHD and with a functional immune system
able to launch a robust human T cell-dependent response. Human adaptive immune responses
are HLA-restricted, implying that maintaining HLA compatibility is a requirement for normal
human immune responses. Currently, no experimental preclinical mouse model can meet this
requirement, including recently developed models such NSG[19], NOG or NRG mice. Thus,
after hPBMC transferred, a rapid onset of xenogeneic Graft-versus-Host Disease (xeno-
GvHD) is observed in all hPBMC-NSG mice. These mice exhibited weight loss, diarrhea, alo-
pecia and pathological infiltration of activated human lymphocytes in liver, skin, or intestine,
leading finally to death after 20 to 25 days[20]. It is interesting to note that the removal of
murine MHC class I activity greatly reduces human in vitro T cell proliferative responses to
Fig 5. Flow cytometry analysis after five and eight weeks of hPBMC transplantation in HUMAMICE. Flow cytometry analysis was done at five, eight
weeks and three months after the hPBMC were transferred. Results of two representative mice (from nine analyzed mice) which were analyzed at five and
eight weeks after transplantation are shown in Fig 5. (A) For the mouse which was analyzed at 5 weeks after transplantation, 11.6% of splenocytes were
composed by hCD45+ cells, with 45.2% of this population being hCD19+, and 17.1% being hCD45+hCD3+ T lymphocytes: 29.0% of them were hCD3+CD8+
and 60.9% were hCD3+CD4+ T cells. (B) For the mouse which was analyzed at 8 weeks after transplantation, 9.7% of splenocytes were composed by
hCD45+ cells, with 49.4% of this population being hCD19+, and 16.1% being T lymphocytes: 30.0% of them were hCD3+CD8+ and 59.0% were hCD3+CD4+
T lymphocytes.
https://doi.org/10.1371/journal.pone.0173754.g005
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murine cells and should thus lead to reduced xenogeneic GvHD following engraftment with
human PBMC[21]. After HLA-matched hPBMC transferred, our mice did not develop any
evidence of GvHD during the three month follow up period.
In present study, we developed a new improved immuno-deficient HUMAMICE model
(HLA-A2+/+/DR1+/+/H-2-β2m
-/-/IAβ-/-/Rag2-/-/IL2rγ-/-/Perf-/-) which could satisfy this
requirement.
Fig 6. The evaluation of body weight of HUMAMICE after hPBMC transplantation. The average weight
is shown as a percentage of starting weight. None of the HUMAMICE developed weight loss after hPBMC
transplantation.
https://doi.org/10.1371/journal.pone.0173754.g006
Fig 7. The humoral immune response of hPBMC-HUMAMICE after immunization with HBsAg vaccine. (A) The HBsAg specific IgG
and (B) HBsAg specific IgM responses of immunized hPBMC-HUMAMICE before (0 w) and every two weeks after immunization (before each
immunization boost).
https://doi.org/10.1371/journal.pone.0173754.g007
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Indeed, the HUMAMICE strain is an immuno-deficient strain with a humanized immune
microenvironment expressing both HLA class I and class II molecules, and which overcomes
the lack of central thymic and peripheral human T-cell maturation through selective interac-
tion with HLA class I and II molecules. The HUMAMICE lack almost all essential murine
immune cells, as similarly demonstrated in NSG, NOG or NRG mouse model. In particular, a
significant reduction of NK cells could favor the engraftment of foreign cells.
The proliferation of RAMOS tumor cells in immuno-deficient HUMAMICE but not in the
parental immuno-competent Sure-L1 mice, and the subsequent tumor elimination by the
transfer of immune cells from RAMOS-rejected Sure-L1 mice, confirmed the severe immuno-
deficiency status of HUMAMICE. Interestingly, HUMAMICE could also be used as a readout
system–together with their parental Sure-L1 mice or Sure-L1-TGFP mice (where all T cells co-
express the GFP protein) or Sure-L1-FoxP3-GFP mice (where T cells co-expressed FoxP3 pro-
tein and GFP protein as fusion protein) to dissect the contribution role of each cell population
to the protective immune responses against foreign antigens like pathogens. The present data
indicated that all immune cells including T cells (CD3+CD4+, CD3+CD8+), B cells, and NK
cells were involved in rejection of the RAMOS tumor.
After transferring 107 HLA-matched (HLA-A2+DR1+) hPBMC cells intravenously into
HUMAMICE, we found hCD45+ cells in splenocytes of HUMAMICE, which included
both human B cells (hCD45+hCD19+) and human T cells (hCD45+hCD3+hCD4+ and
hCD45+hCD3+hCD8+). More importantly, none of HUMAMICE developed any GvHD
signs or weight loss after HLA-A2+DR1+ hPBMC were transferred.
Because of limited availability HLA-A2+DR1+ PBMCs from two donors, we could only per-
form one analysis in one mouse at 3 months after transfer of human PBMCs. At this time
point, we detected around 42% hCD45+hCD19+ compared to 12% hCD45+ hCD3+ cells.
These B cells (42%) could optimally interact with both reconstituted hAPC and hCD4+ cells.
In addition, they could also interact with mAPC which expressed HLA-A2 and DR1. This
could explain how both HBsAg-specific hIgG and hIgM antibodies are induced in our model.
Our research indicated successful engraftment of hPBMCs in this new immuno-deficient
HLA-humanized mouse model-HUMAMICE.
In the model of Xeno-GvHD, after intravenous transfer of hPBMCs in RAG2-/-c-/- mice[22],
high engraftment rates of human cells had been reported between 2 to 4 weeks after transplanta-
tion, with a T-cell chimerism of at least 20–48% in more than 90% of mice. This high engraft-
ment rate was associated with the development of acute Xeno-GvHD and a mortality rate of
85% of the mice within 2 months. Interestingly only a small population of B cells (around
7–11%) residing in lymphoid compartments were detected in these mice explaining the detec-
tion of elevated plasma levels of IgG and IgM. In fact, it has also been reported that immuno-
globulin production in hPBMC-SCID models could be high despite low numbers of B cells and
was generally used as an indication of good engraftment of the human cells[23, 24, 25].
Conclusions
The HUMAMICE model represents an improvement over the traditional immuno-deficient
mice models like NSG and NOG mice, which have drawbacks such as development of xeno-
GVHD. The HLA-compatible-hPBMC-HUMAMICE is thus a unique model that could be
used to explore human immunology in a normal physiological situation (without xeno-
GvHD) and could be useful for evaluation of cell-therapies, generation of human monoclonal
antibodies, and production of novel vaccines.
Nonetheless, it should be noted that the new Humamice mice were made on the C57BL/6
genetic background, and then backcrossed for 7 generations, and not originally on the NOD
Mouse model for studying human immunity
PLOS ONE | https://doi.org/10.1371/journal.pone.0173754 April 11, 2017 13 / 17
background. The genetic background of the mice will impact the ability of the mice to sustain
long-term engraftment of human HSC and PBMC in several immunodeficient strains. It was
previously shown that NOD-scid mice supported higher levels of engraftment with human
PBMCs than other strains tested, including C3H/HeJ-scid and C57BL/6-scid mice[26, 27].
More recently, it was shown that the NSG (NOD-scid IL2rγnull) mouse model supports
higher levels of human hemato-lymphoid engraftment than BALB/c-Rag1null IL2rγnull mice
[28], and that NOD-Rag1null IL2rγnull mice also engraft with human PBMC at higher levels
than NOD-scid IL2rγnull mice[29]. These data indicate that the difference of human PBMC
engraftment between NOD-scid IL2rγnull and BALB/c-Rag2null IL2rγnull mice is not due to
scid vs. Rag1null or Rag2null genes but rather to genetic polymorphic background modifiers.
Genomic studies showed that these background modifiers are localized to the Idd13 locus,
which encodes the Sirp gene. SIRP is mainly expressed by macrophages, DCs, and neutrophils,
and its ligand, CD47, is expressed almost ubiquitously. The SIRP–CD47 interaction is involved
in regulating macrophage-mediated phagocytosis by delivering a licensing signal to macro-
phages[30]. The NOD SIRP-α protein is more similar to the human SIRP-α protein than the
C57BL/6 SIRP-α protein.It shows enhanced binding to the human CD47 ligand, and its
expression on mouse macrophages leads to better support of human hematopoiesis[31]. The
role of murine macrophages in the rejection of human cells and prevention of human reconsti-
tution was confirmed when more successful engraftment rates of human cells were observed
in neonate recipients that had lower macrophage activity and in adult murine hosts after
depletion of macrophages following intraperitoneal injection of clodronate[32].
Moreover, NSG mice engraft with human PBMC better than H2d-Rag2null IL2rγnull mice.
The production of NSG mice provides an immunodeficient mouse model lacking host NK
cells, facilitating human PBMC engraftment. NSG mice support survival of engrafted human
T cells, but the human cells mount a severe xenogeneic GvHD following engraftment into NK
cell-deficient hosts.
In the present study, we made immuno-deficient HUMAMICE mice, which are mouse
MHC Class I and Class II deficients, and express both HLA-A2 and HLA-DR1. It is interesting
to note that the removal of mouse MHC class I activity greatly reduces human in vitro T cell
proliferative responses to murine cells[33] and should lead to reduced xenogeneic GVHD fol-
lowing engraftment with human PBMC. This hypothesis was supported by experiments where
PBMC were injected intravenously into NOD-scid β2mnull mice via the tail vein, resulting in
transient engraftment and failing to induce xenogeneic GvHD[34]. Furthermore, it was previ-
ously shown that NOD-scid β2m
null mice support higher levels of human PBMC engraftment
than NOD-scid mice[35], because in the absence of β2m, natural killer (NK) cell numbers and
activity are severely depressed due to the lack of MHC class I expression[35].More importantly,
the absence of β2m in host cells reduces xenogeneic GVHD responses of the human T cells. In
addition, macrophages in HUMAMICE express both HLA-A2 and HLA-DR1, which are com-
patible with grafted human PBMC. In this HLA-matched situation, there are no allo-like or
xeno-like rejection reactions, so the non-optimal mSIRP–hCD47 interaction does not affect
long-term PBMC engraftment. However, it must be noted that HUMAMICE is not a good
model for engraftment of non-HLA-matched PBMC or any human stem cells, including human
HSCs, due to the NOD genetic background of the HUMAMICE and the lack of supporting cyto-
kines, cytokines, supporting cells such as stromal cells, and human APCs in the mice.
In conclusion, despite some of the drawbacks listed above, the HLA-matched-hPBMC-HU-
MAMICE model allows the possibility of studying normal human immune responses in vari-
ous human diseases, including infectious diseases and cancer in the HLA-matched population.
It also represents a promising model for facilitating the development of novel vaccines and cel-
lular therapies.
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